Pion Audrey, Kavanagh Erin, Joynt Anya T, Raraigh Karen S, Vanscoy Lori, Langfelder-Schwind Elinor, McNamara John, Moore Brooke, Patel Shivani, Merlo Kate, Temme Renee, Capurro Valeria, Pesce Emanuela, Merlo Christian, Pedemonte Nicoletta, Cutting Garry R, Sharma Neeraj
Department of Genetic Medicine.
Department of Pediatrics, and.
Am J Respir Cell Mol Biol. 2024 Nov;71(5):577-588. doi: 10.1165/rcmb.2023-0398OC.
We broaden the clinical versatility of human nasal epithelial (HNE) cells. HNEs were isolated from 10 participants harboring () variants: 9 with rare variants (Q359R [=2], G480S, R334W [=5], and R560T) and 1 harboring R117H;7T;TG10/5T;TG12. Cultures were differentiated at the air-liquid interface. CFTR function was measured in Ussing chambers at three conditions: baseline, ivacaftor, and elexacaftor + tezacaftor + ivacaftor (ETI). Four participants initiated modulators. Q359R HNEs had 5.4% (% wild-type) baseline CFTR function and 25.5% with ivacaftor. With therapy, sweat [Cl] decreased and symptoms resolved. G480S HNEs had 4.1% baseline and 32.1% CFTR function with ETI. Clinically, forced expiratory volume in 1 second increased and sweat [Cl] decreased (119 to 46 mmol/L) with ETI. cultures derived from 5 participants harboring R334W showed a moderate increase in CFTR function with exposure to modulators. For one of these participants, ETI was begun ; symptoms and forced expiratory volume in 1 second improved. The c.1679G>C (R560T) HNEs had less than 4% baseline CFTR function and no modulator response. RNA analysis confirmed that c.1679G>C completely missplices. A symptomatic patient harboring R117H;7T;TG10/5T;TG12 exhibited reduced CFTR function (17.5%) in HNEs, facilitating a diagnosis of mild CF. HNEs responded to modulators (ivacaftor: 32.8%, ETI: 55.5%), and, since beginning therapy, lung function improved. We reaffirm HNE use for guiding therapeutic approaches, inform predictions on modulator response (e.g., R334W), and closely assess variants that affect splicing (e.g., c.1679G>C). Notably, functional studies in HNEs harboring R117H;7T;TG10/5T;TG12 facilitated a diagnosis of mild CF, suggesting the use for HNE functional studies as a clinical diagnostic test.
我们拓宽了人鼻上皮(HNE)细胞的临床应用范围。从10名携带()变体的参与者中分离出HNE细胞:9名携带罕见变体(Q359R[=2]、G480S、R334W[=5]和R560T),1名携带R117H;7T;TG10/5T;TG12。细胞培养在气液界面进行分化。在三种条件下于尤斯灌流小室中测量CFTR功能:基线、依伐卡托,以及依列卡托+替扎卡托+依伐卡托(ETI)。4名参与者开始使用调节剂。Q359R HNE细胞的基线CFTR功能为5.4%(野生型百分比),使用依伐卡托时为25.5%。经过治疗,汗液[Cl]降低,症状缓解。G480S HNE细胞的基线CFTR功能为4.1%,使用ETI时为32.1%。临床上,使用ETI后,一秒用力呼气量增加,汗液[Cl]降低(从119降至46 mmol/L)。来自5名携带R334W变体参与者的细胞培养物在接触调节剂后CFTR功能有适度增加。其中一名参与者开始使用ETI;症状和一秒用力呼气量均有改善。c.1679G>C(R560T)HNE细胞的基线CFTR功能低于4%,且对调节剂无反应。RNA分析证实c.1679G>C完全剪接错误。一名携带R117H;7T;TG10/5T;TG12的有症状患者的HNE细胞中CFTR功能降低(17.5%),有助于诊断轻度囊性纤维化(CF)。HNE细胞对调节剂有反应(依伐卡托:32.8%,ETI:55.5%),并且自开始治疗以来,肺功能有所改善。我们重申使用HNE细胞来指导治疗方法、预测调节剂反应(例如R334W),并密切评估影响剪接的变体(例如c.1679G>C)。值得注意的是,对携带R117H;7T;TG10/5T;TG12的HNE细胞进行的功能研究有助于诊断轻度CF,表明将HNE细胞功能研究用作临床诊断测试。